Stocks Climb on Trump Remark of “Many Trade Deals” Being Close
Stocks gained Friday as President Donald Trump suggested many trade deals are near, while also endorsing cutting the tariff rate on China before weekend talks.The Dow Jones Industrials retreated 55.54 points to 41,312.91.The S&P 500 index deleted 2.87 points to 5,661.07.The NASDAQ Composite fell 5.09 points to 17,924.05. Traders hope the U.K. agreement will establish a framework for the U.S. to quickly strike more deals with major nations, even though a 10% tariff rate on the U.K. appears to be the baseline for the globe.The president also wrote on Truth Social that an “80% Tariff on China seems right” ahead of talks lead by Treasury Secretary Scott Bessent with China counterparts in Switzerland this weekend.While this is a de-escalation somewhat from the current 145% tariff on China, it’s still higher than many expected where the administration would go to jumpstart talks. Bloomberg News had reported earlier that the rate could be lowered below 60% as soon as this week.It was also unclear if the president is talking about a long-term tariff rate on China or a temporary one during negotiations.Prices for the 10-year Treasury moved forward, lowering yields to 4.34% from Thursday’s 4.39%. Treasury prices and yields move in opposite directionsOil prices prospered 41 cents to $60.32 U.S. a barrel. Prices for gold revived $24.60 to $3,330.60 U.S.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


